Clinical Trials Logo

Adiposity clinical trials

View clinical trials related to Adiposity.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06343987 Recruiting - Clinical trials for Metastatic Breast Cancer

The FEMA Study: Feasibility of Exercise in Patients With Metastatic Breast Cancer and Adiposity

Start date: February 19, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to test a physical activity program in patients with metastatic breast cancer and overweight receiving endocrine-based treatment. The aim of the study is to assess the feasibility and metabolic efficacy of a 12-week physical activity program in this patient group. The hypothesis is that improving metabolic health through physical activity can optimize cancer care. Participants will randomized 2:1 to either a physical activity program or care as usual.

NCT ID: NCT06223035 Recruiting - Adiposity Clinical Trials

Myokine Identification Following Acute Exercise

Start date: April 18, 2024
Phase: N/A
Study type: Interventional

Exercise stimulates a cascade of responses within the human body. For example, exercise results in the release of proteins into the circulation which communicate with cells and organs throughout the body. In fact, recent human research identified more than 600 proteins are released into the blood circulation following short-term exercise, many of which are predicted to come from the skeletal muscle and target the fat tissue. However, identification of these muscle-secreted proteins and their target tissue (i.e. fat tissue) remains extremely challenging. This challenge is because tissue needs to be collected from multiple sites (skeletal muscle and fat) and at multiple timepoints (before and after exercise). This study seeks to address these challenges through the collection of fat and blood both before and after short-term exercise followed by protein detection (of the blood) and gene expression (of the fat tissue).

NCT ID: NCT06208345 Recruiting - Childhood Obesity Clinical Trials

Early Life Intervention in Pediatrics Supported by E-health

ELIPSE-I
Start date: February 16, 2024
Phase: N/A
Study type: Interventional

Childhood obesity in early life contributes to the development of specific NCDs, i.e. adult obesity. Unhealthy diet and low level of physical activity are lifestyle risk behaviors associated with chronic, systemic inflammation, which promotes the pathogenesis of NCDs. Early preventive measures to improve lifestyle behavior are of utmost importance. The aim of ELIPSE-I is to assess whether an eHealth application intervention for parents is feasible and efficacious in lowering total energy intake/total energy expenditure (TEI/TEE) ratio in their children with BMI >97 centile (ELIPSE-I).

NCT ID: NCT06189001 Recruiting - Adiposity Clinical Trials

The Role of Oxytocin-receptor Signalling in Physiological Regulation of Eating Behaviour in Individuals With Obesity

FOxy
Start date: January 1, 2024
Phase: N/A
Study type: Interventional

The present study evaluates appetite, glucose metabolism, gastrointestinal motility and energy expenditure in men and women with obesity (BMI 30-40 kg/m2) under oxytocin exposure compared to placebo.

NCT ID: NCT06153654 Recruiting - Adiposity Clinical Trials

Role of the Nasal Environment in Obesity

Start date: July 30, 2021
Phase:
Study type: Observational

The primary aim of this study is to investigate the nasal environment in obese and lean individuals.

NCT ID: NCT06129110 Recruiting - Obesity Clinical Trials

Effect of Weight Loss on Intermuscular Adipose Tissue (IMAT) Signaling

Start date: January 1, 2024
Phase: N/A
Study type: Interventional

The goal of this intervention study is to learn about how weight loss impacts molecular signaling of intermuscular adipose tissue (IMAT) in individuals with obesity. The main question it aims to answer is how inflammatory molecules secreted by IMAT promote muscle insulin resistance and inflammation, and how these same molecules are diminished after weight loss. Following screening visits involving body composition measures, blood testing, strength testing, and a thigh muscle biopsy, participants will go through a 12-week dietary intervention for weight loss. After 12 weeks, this will be followed by the same testing and biopsies that were completed before the intervention. Researchers will then compare outcomes of individuals who lost weight to individuals who did not lose weight.

NCT ID: NCT05992688 Recruiting - Insulin Sensitivity Clinical Trials

The Sweet Kids Study (Stevia on Weight and Energy Effect Over Time)

Start date: September 19, 2023
Phase: N/A
Study type: Interventional

This is an 8 to14-week three-arm randomized controlled in children 8 to 12 years old. The main purpose of the study is to evaluate if stevia (as with other sweeteners and consistent with prior research in children and adults) has benefits for weight control and metabolic function relative to caloric sweeteners, and whether it provides benefits in this regard similar to water.

NCT ID: NCT05962190 Recruiting - Adiposity Clinical Trials

Short-term Fat Overfeeding on the Effects of Liver Metabolism

FOS
Start date: February 15, 2023
Phase: N/A
Study type: Interventional

Despite work showing the overconsumption of saturated fatty acids (SFA) to be metabolically deleterious, debate continues about whether there is a link between SFA and cardiovascular disease risk. To explore this, we are undertaking a human in vivo parallel-design study, comparing two isocaloric high-fat diets; one enriched with SFA and the other enriched with unsaturated fatty acids (UFAs), to determine the impact of dietary fat composition on postprandial metabolism, liver fat, cardiac fat and cardiac function.

NCT ID: NCT05703802 Recruiting - Sepsis Clinical Trials

Establishment of an ELISA for the Recognition of Procalcitonin Variants in Patients With Hyperprocalcitonemia.

Start date: July 1, 2022
Phase:
Study type: Observational [Patient Registry]

Procalcitonin is a protein consisting of 116 amino-acids which can rapidly rise under inflammatory conditions and sepsis. More than 20 years ago it has been shown that dipeptidylpeptidase-4 (DPP-4) cleaves procalcitonin from the n-terminus, resulting in a truncated procalcitonin-variant which consists of 114 aminoacids. Within our workgroup we found that the truncated procalcitonin-variant had deleterious effects on vascular integrity during sepsis in mice. However, it is unknown if this applies also in humans. By using an ELISA-assay we want to examine the ratio between native and truncated human procalcitonin during diseases accompanied with hyperprocalcitoninemia and correlate the results with clinical data.

NCT ID: NCT05587491 Recruiting - Obesity Clinical Trials

HybridAPC for Gastric Mucosal Ablation in Obese Patients.

Start date: February 27, 2023
Phase: N/A
Study type: Interventional

This study is intended to investigate safety and feasibility of a new weight loss technique called Gastric Mucosal Ablation (GMA) that does not require surgery, but can be achieved using an endoscopic procedure. Previous studies have suggested that weight loss after vertical sleeve gastrectomy (VSG) is partly due to the removal of normal stomach tissue suspected of having hormonal function. The study will investigate the minimally invasive treatment of obese participants by means of argon plasma coagulation (APC) in combination with waterjet submucosal injection using HybridAPC. As primary endpoint the % total body weight loss (TBWL) will be determined as body weight difference at the final 6 months FU after the last treatment session in comparison to the body weight prior to the initial treatment. After signing the informed consent the doctor and research team will determine if the participant meets all requirements for this study. If a participant is confirmed to be a suitable candidate additional tests will be performed prior to the first application of GMA to assess the health status of the participant prior to treatment. During the screening and baseline visit the medical history and the medications of the participant will be reviewed. After the treatments the participants will be followed for up to 6 months to assess the outcome of the GMA procedure.